LPL Financial
MGX icon

LPL Financial’s Metagenomi Therapeutics MGX Stock Holding History

LPL Financial’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.6K Buy
16,834
+5,537
+49% +$8.6K ﹤0.01% 5866
2025
Q4 		$18.3K Buy
+11,297
New +$24.5K ﹤0.01% 5814

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LPL Financial's MGX Position: Q1 2026 in Review

LPL Financial increased its Metagenomi Therapeutics (MGX) stake by 49% in Q1 2026, buying an estimated $8.6K and bringing the position to 16,834 shares worth $22.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5866.

LPL Financial first reported a position in MGX in Q4 2025 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • LPL Financial held 16,834 shares of Metagenomi Therapeutics worth $22.6K as of Q1 2026.
  • LPL Financial bought 5,537 Metagenomi Therapeutics shares in Q1 2026, an estimated $8.6K.
  • Metagenomi Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5866 holding.
  • LPL Financial first reported a position in Metagenomi Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.